HomeCompareMSGRX vs JNJ

MSGRX vs JNJ: Dividend Comparison 2026

MSGRX yields 8.55% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MSGRX wins by $15.2K in total portfolio value
10 years
MSGRX
MSGRX
● Live price
8.55%
Share price
$11.23
Annual div
$0.96
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$35.2K
Annual income
$1,466.75
Full MSGRX calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — MSGRX vs JNJ

📍 MSGRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMSGRXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MSGRX + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MSGRX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MSGRX
Annual income on $10K today (after 15% tax)
$726.59/yr
After 10yr DRIP, annual income (after tax)
$1,246.74/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, MSGRX beats the other by $543.12/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MSGRX + JNJ for your $10,000?

MSGRX: 50%JNJ: 50%
100% JNJ50/50100% MSGRX
Portfolio after 10yr
$27.6K
Annual income
$1,147.27/yr
Blended yield
4.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

MSGRX
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MSGRX buys
0
JNJ buys
0
No recent congressional trades found for MSGRX or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMSGRXJNJ
Forward yield8.55%3.36%
Annual dividend / share$0.96$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$35.2K$20.0K
Annual income after 10y$1,466.75$827.78
Total dividends collected$11.6K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MSGRX vs JNJ ($10,000, DRIP)

YearMSGRX PortfolioMSGRX Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,555$854.82$10,676$355.77+$879.00MSGRX
2$13,287$923.11$11,407$389.39+$1.9KMSGRX
3$15,209$992.03$12,198$426.53+$3.0KMSGRX
4$17,335$1,061.25$13,056$467.62+$4.3KMSGRX
5$19,679$1,130.46$13,987$513.12+$5.7KMSGRX
6$22,255$1,199.36$14,998$563.56+$7.3KMSGRX
7$25,081$1,267.68$16,098$619.52+$9.0KMSGRX
8$28,172$1,335.16$17,295$681.69+$10.9KMSGRX
9$31,546$1,401.58$18,599$750.82+$12.9KMSGRX
10$35,220$1,466.75$20,022$827.78+$15.2KMSGRX

MSGRX vs JNJ: Complete Analysis 2026

MSGRXStock

The fund seeks long-term growth of capital by investing, under normal circumstances, at least 80% of its net assets, including the amount of any borrowings for investment purposes, in equity securities (including common stocks, preferred stocks and securities convertible into common and preferred stocks) of U.S. small capitalization companies. It may also invest up to 20% of its net assets in securities of companies of any market capitalization.

Full MSGRX Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this MSGRX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MSGRX vs SCHDMSGRX vs JEPIMSGRX vs OMSGRX vs KOMSGRX vs MAINMSGRX vs ABBVMSGRX vs MRKMSGRX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.